Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, CLIA, Agilent, Gene Logic

Affy's Clinical Services Lab Clears CLIA
Affymetrix said this week that its Clinical Services Lab has been certified to begin offering microarray-based molecular diagnostic testing under Clinical Laboratory Improvement Amendments.
The ACSL, a 10,000 square-foot lab in Sacramento, Calif., will be used for clinical trial and patient testing, the company said. The facility's offerings include gene expression monitoring, genotyping, chromosomal copy number analysis, and other molecular diagnostic tests. Affy said that the lab has already signed two agreements with customers.
CLIA certification ensures that the lab's processes meet standards for accuracy, precision, sensitivity, calibration, and control under federal and Clinical Laboratory Standards Institute regulations. All of the lab's assays have also been validated for clinical applications, the company said. Affy said the lab received the clearance on April 9.

Agilent, Gene Logic to Improve Techniques for 'Systems-Based' Drug Research
Agilent Technologies and Gene Logic intend to improve tools and techniques for systems-based biopharmaceutical research, including clinical profiling and pathway mapping, the companies said this week. Gene Logic also said it has become an Agilent Certified Microarray Service Provider.
Under the collaboration, Agilent will provide microarray workflow products, including its GeneSpring bioinformatics platform, while Gene Logic will contribute its biorepository and other databases, the companies said.
The companies said the relationship will also tap their “channels into academic and commercial life science sectors.”
The companies said they are also exploring integrating data from microarray platforms into breast cancer research by conducting array-based comparative genomic hybridization, microRNA, gene-expression methods, and SNP-genotyping studies on tissues from Gene Logic’s tissue repository.
The companies said early results from the studies show a “good correlation” between aCGH and gene expression data, “which could be useful in developing a therapy.”

Agilent Debuts New Life Sciences HQ in China
Agilent Technologies has opened a dual-duty headquarters in Beijing that will house life sciences research and commercial facilities, the company said last week.
Max Yang, Agilent’s vice president and general manager of its Greater China operations, said the company’s “long-term objective” is to become “further rooted in China and help drive the development of local industries.”
The Life Sciences and Chemical Analysis Center of Excellence and the Agilent Open Lab and Solution Center are situated at the Beijing Want Jing Science Park, the company said. The facilities will handle R&D, sales, marketing, technical support, and after-sale functions.
The company said the LSCA center will demonstrate Agilent’s bio-analytical-measurement products, and customers will be able to interact with specialists and management. The OLSC, meantime, will focus on testing and consulting for electronic measurement customers.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.